RT Journal Article
SR Electronic
T1 Lessons from the PROVE-IT Trial
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 609
OP 616
VO 71
IS 8
A1 Khush, Kiran K.
A1 Waters, David
YR 2004
UL http://www.ccjm.org/content/71/8/609.abstract
AB The Pravastatin or Atorvastatin Evaluation and Infection Therapy trial (PROVE-IT/TIMI-22) showed that in patients with acute coronary syndromes, aggressive lipid-lowering using atorvastatin 80 mg/day provided greater protection against death or major cardiovascular events than did moderate lipid-lowering using pravastatin 40 mg/day. Lowering the low-density lipoprotein cholesterol level to approximately 62 mg/dL with atorvastatin resulted in a 16% reduction in cardiovascular end points.